We speculate that increased PARP-1 expression may enhance the release of inflammatory substances by increasing NF-κB expression, which may be the primary cause for low-dose captopril treatment on CHF without inhibiting TNF-α. The gene discussed is TNF; the disease is congestive heart failure.